Raymond James & Associates Catalyst Biosciences, Inc. Transaction History

Raymond James & Associates

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$0.2 - $0.35 $10,000 - $17,500	-50,000 Reduced 79.49%	12,900 $4,000
Q1 2023 Apr 14, 2023	BUY	$0.19 - $0.64 $5,772 - $19,443	30,380 Added 93.42%	62,900 $13,000
Q4 2022 Feb 08, 2023	SELL	$0.49 - $0.57 $6,664 - $7,751	-13,600 Reduced 29.49%	32,520 $17,000
Q3 2022 Oct 25, 2022	BUY	$0.49 - $1.95 $6,673 - $26,559	13,620 Added 41.91%	46,120 $23,000
Q1 2022 May 11, 2022	SELL	$0.51 - $1.0 $153 - $300	-300 Reduced 0.91%	32,500 $21,000
Q4 2021 Feb 08, 2022	SELL	$0.91 - $4.16 $88,045 - $402,492	-96,753 Reduced 74.68%	32,800 $30,000
Q3 2021 Nov 02, 2021	SELL	$3.78 - $5.18 $21,077 - $28,883	-5,576 Reduced 4.13%	129,553 $532,000
Q2 2021 Aug 11, 2021	BUY	$4.1 - $5.33 $30,446 - $39,580	7,426 Added 5.82%	135,129 $585,000
Q1 2021 May 14, 2021	SELL	$4.93 - $7.15 $203,189 - $294,687	-41,215 Reduced 24.4%	127,703 $644,000
Q4 2020 Feb 12, 2021	BUY	$4.55 - $7.29 $435,507 - $697,769	95,716 Added 130.76%	168,918 $1.07 Million
Q3 2020 Nov 04, 2020	BUY	$4.22 - $6.04 $59,080 - $84,560	14,000 Added 23.65%	73,202 $315,000
Q2 2020 Jul 28, 2020	BUY	$3.76 - $8.01 $222,599 - $474,208	59,202 New	59,202 $348,000
Q1 2018 May 14, 2018	SELL	$14.18 - $35.6 $608,180 - $1.53 Million	-42,890 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$4.52 - $13.69 $193,862 - $587,164	42,890	42,890 $585,000

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.